Akebia Therapeutics Stock News

Tricida Provides Regulatory Update on Veverimer

Akebia Therapeutics (AKBA) has announced the initiation of an investigator-sponsored study evaluating the use of vadadustat as a potential therapy to prevent and lessen the severity of acute respirato

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced the initiation of an investigator-sp

ValuEngine lowered shares of Akebia Therapeutics (NASDAQ:AKBA) from a buy rating to a hold rating in a research report released on Monday morning, ValuEngine reports. Several other brokerages also rec

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV)...

If you want to know who really controls Akebia Therapeutics, Inc. (NASDAQ:AKBA), then you'll have to look at the...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase

A simple two-rule screen can help you pick R&D-intensive stocks primed to outperform. The differences between R&D expenditures and capital expenditures vary bet

AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Rita Jain, M.D., to the Company

The 117-year-old apolitical Sikh organisation Chief Khalsa Diwan (CKD) passed approximately Rs 147 crore budget for 2020-21 in the meetings of executive committee and General...

Needham analyst Chad Messer assigned a Buy rating to Akebia Therapeutics (AKBA – Research Report) today and set a price

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first regulatory approval of vada

Local Chagrin Falls Businesses Facilitate Education by Launching a Healthy Home Webinar Series CHAGRIN FALLS, Ohio (PRWEB) June 24, 2020 Anne Capozzi, president of Capozzi Design Group of Chagrin

Akebia Therapeutics (NASDAQ:AKBA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Monday, Zacks.com reports. The firm presentl

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev